Ex-Cedilla CEO Glucksmann explores ‘new frontier’ at Sensorium; R&D chief out at Merck women’s health spinoff Organon
08 Dec 2023
Executive Change
Alexandra Glucksmann is always looking for “the next frontier” in medicine. After spending most of her career in genetic diseases, rare diseases and oncology, her next pursuit is in mental health.
The longtime biopharma executive is the next CEO at Sensorium Therapeutics, a biotech leveraging machine learning to develop new mental health treatments, starting from plant components that are known to be psychoactive. The company’s lead program in anxiety is currently in preclinical testing.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.